Equity Profile

TMDX

TransMedics Group, Inc.

Health CareHealth Care Equipment$2.4B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

TransMedics Group, Inc. is a healthcare company focused on innovative organ transplant solutions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will indicate how well the company is expanding its market presence and attracting new customers.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TMDX Q2-2026 Earnings Preview

Context

Company Snapshot

TransMedics Group, Inc. is a healthcare company focused on innovative organ transplant solutions. Their technology aims to improve the success rates of organ transplants, which is critical in addressing the growing need for organ donations.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+101.46%

Avg Stock Reaction

+0.63%

Last Quarter Recap

In Q1-2026, TransMedics reported an EPS of $0.30, which was significantly below the expected $0.62, resulting in a stock decline of 2.21% the following day. The company did not provide revenue figures or guidance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has had a history of earnings surprises, but recent performance raises concerns about future growth.

Bull Case

If TransMedics can demonstrate strong revenue growth and improved profitability, it could regain investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet earnings expectations again, it may lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the significant miss last quarter, investors will closely scrutinize EPS to gauge the company's recovery trajectory.

How is revenue growth tracking compared to previous quarters?

Revenue growth is critical for assessing the company's market position and ability to attract new customers.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for TransMedics to rebound after a disappointing quarter, as their innovative technology could still attract significant interest.

Supporting Evidence

The options market is pricing a 37.24% move, suggesting that traders expect significant volatility.

Historically, the company has a 75% EPS beat rate, indicating a strong potential for positive surprises.

Recent performance trends show that the company has the capacity for rapid recovery, as seen in previous quarters.

Key Risk

If the EPS comes in above $0.50, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around whether the company can recover from its last earnings miss and show tangible growth.

Bull Confirmed If

A positive EPS surprise of $0.50 or better would confirm the bull case.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±37.24%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±37.2% while TMDX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

92.1%

Calls (97K)P/C Ratio: 2.57Puts (106K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TransMedics beats expectations, history suggests a potential stock increase of around 1.07%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable but could be influenced by management's commentary.

Miss

A miss could lead to a decline of approximately 0.68%, reflecting ongoing investor concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships.
2Details on customer acquisition strategies and market expansion efforts.
3Insights into operational efficiencies and cost management.
4Management's outlook on the organ transplant market and demand trends.
5Any commentary on competitive positioning and differentiation.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

TransMedics Group, Inc. is a healthcare company focused on innovative organ transplant solutions....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating income.

N/A

Revenue Growth

Revenue growth will indicate how well the company is expanding its market presence and attracting new customers.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

TMDX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+101.46%

Avg Stock Reaction

+0.63%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has had a history of earnings surprises, but recent performance raises concerns about future growth.

Bull Case

If TransMedics can demonstrate strong revenue growth and improved profitability, it could regain investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet earnings expectations again, it may lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the significant miss last quarter, investors will closely scrutinize EPS to gauge the company's recovery trajectory.

How is revenue growth tracking compared to previous quarters?

Revenue growth is critical for assessing the company's market position and ability to attract new customers.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for TransMedics to rebound after a disappointing quarter, as their innovative technology could still attract significant interest.

Supporting Evidence

The options market is pricing a 37.24% move, suggesting that traders expect significant volatility.

Historically, the company has a 75% EPS beat rate, indicating a strong potential for positive surprises.

Recent performance trends show that the company has the capacity for rapid recovery, as seen in previous quarters.

Key Risk

If the EPS comes in above $0.50, it could challenge the current cautious sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis this quarter revolves around whether the company can recover from its last earnings miss and show tangible growth.

Bull Confirmed If

A positive EPS surprise of $0.50 or better would confirm the bull case.

Bear Confirmed If

An EPS below $0.20 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±37.24%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±37.2% while TMDX has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

92.1%

Calls (97K)P/C Ratio: 2.57Puts (106K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If TransMedics beats expectations, history suggests a potential stock increase of around 1.07%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable but could be influenced by management's commentary.

Miss

A miss could lead to a decline of approximately 0.68%, reflecting ongoing investor concerns about the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships.
2Details on customer acquisition strategies and market expansion efforts.
3Insights into operational efficiencies and cost management.
4Management's outlook on the organ transplant market and demand trends.
5Any commentary on competitive positioning and differentiation.